Literature DB >> 1021238

Phase II evaluation of cis-diamminedichloroplatinum(II) in lung cancer.

A H Rossof, J D Bearden, C A Coltman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 1021238

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  6 in total

Review 1.  Chemotherapy of advanced non-small cell lung cancer. A review.

Authors:  B J Takasugi; T P Miller
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

2.  Chemotherapy of non-small cell lung cancer: clinical trials at the Memorial Sloan-Kettering Cancer Center.

Authors:  R J Gralla; R E Wittes; E S Casper; D P Kelsen; E Cvitkovic; G B Magill; S E Krown; R B Golbey
Journal:  World J Surg       Date:  1981-09       Impact factor: 3.352

3.  Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.

Authors:  Y Sasaki; T Shinkai; K Eguchi; T Tamura; Y Ohe; T Ohmori; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Phase II evaluation of fractionated low and single high dose cisplatin in various tumors.

Authors:  R B Schilcher; M Wessels; N Niederle; S Seeber; C G Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

5.  Cisplatin, vinblastine, and bleomycin in inoperable non-small cell lung cancer.

Authors:  R Stuart-Harris; R M Fox; D Raghavan; A S Coates; D Hedley; J A Levi; R L Woods; M H Tattersall
Journal:  Thorax       Date:  1985-05       Impact factor: 9.139

6.  cis-diamminedichloroplatinum (CDDP) therapy for brain metastasis of lung cancer. II: Clinical effects.

Authors:  H Nakagawa; T Fujita; S Izumimoto; Y Miyawaki; S Kubo; Y Nakajima; K Tsuruzono; K Kodama; M Higashiyama; O Doi
Journal:  J Neurooncol       Date:  1993-04       Impact factor: 4.130
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.